Editorial Comment from Dr Funahashi to Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial

Affiliations

Editorial

Yasuhito Funahashi. Int J Urol. 2022 May.

. 2022 May;29(5):396.

doi: 10.1111/iju.14819. Epub 2022 Feb 15.

¹ Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

No abstract available

Comment on

Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.
Elbaz R, El-Assmy A, Zahran MH, Hashem A, Shokeir AA. Elbaz R, et al. Int J Urol. 2022 May;29(5):390-396. doi: 10.1111/iju.14792. Epub 2022 Jan 18. Int J Urol. 2022. PMID: 35043484 Clinical Trial.

1. Irwin DE, Milsom I, Reilly K et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J. Sex. Med. 2008; 5: 2904-10.
1. Wu T-H, Shen Y-C, Lee W-C et al. Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. J. Chin. Med. Assoc. 2020; 83: 55-9.
1. Dimitriadis F, Zachariou A, Skouros S et al. The impact of mirabegron on erectile functions of males with overactive bladder. J. Sex. Med. 2017; 14: e128.
1. Karakus S, Musicki B. Mirabegron for erectile dysfunction. J. Sex. Med. 2021; 18: S47.
1. Elbaz R, El-Assmy A, Zahran MH, Hashem A, Shokeir AA. Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. Int. J. Urol. 2022; 29: 390-6.